Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial

Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine’s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder

Vancouver, Canada, July 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today provides key insights from its June 10 webinar, “Inside MEAI,” during which the Company’s CEO and the leading investigators of the Company’s ongoing first-in-human clinical trial of CMND-100 (the “Trial”), provided an update based on their "hands-on" experience from the Trial.

Based on the data available to date from the Trial, Dr. Anahita Bassir Nia of Yale School of Medicine and Dr. Jennifer Ellis of Johns Hopkins University have conveyed a generally positive impression of CMND‑100 and the ongoing Phase I/IIa study. They highlighted the significant unmet need in Alcohol Use Disorder (AUD), where currently available treatments are limited in number and often accompanied by notable side effects.

Key points emphasized by the investigators included:

The non-hallucinogenic profile of MEAI, which differentiates it from classical psychedelics. This could enable a much simpler and more accessible treatment model, without the need for hospitalization, intensive monitoring, or mandatory psychological/psychiatric supervision.

The reduced dependence on subjective psychedelic experiences improves blinding and allows for a clearer assessment of the compound’s direct pharmacological effects.